A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects
A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
Inclusion Criteria:
Exclusion Criteria:
Stanford, Connecticut, United States
Witchita, Kansas, United States
Landsdale, Pennsylvania, United States
Capital Federal, Buenos Aires, Argentina
Porta Alegre, Rio Grande do Sul, Brazil
Florian�polis, Santa Catarina, Brazil
Medillin, Antioquia, Colombia
Bogota Dc, Cundianmarca, Colombia
Belvilee, Cape Town, South Africa
Tygerberg, Cape Town, South Africa
Thaba Tswane, Pretoria, South Africa
Distrito Capital, Miranda, Venezuela